A significant proportion of people with chronic kidney disease (CKD) are asymptomatic, and the diagnosis relies on pathologic evidence of kidney damage such as hematuria and/or proteinuria, or laboratory evidence of a reduction in the glomerular filtration rate (GFR) with an elevated serum creatinine.
History
Signs and symptoms vary with stage of disease. They are often vague, and commonly include fatigue (which may be related to uremia or the anemia associated with CKD), nausea, and possibly the development of edema.[49]Meyer TW, Hostetter TH. Uremia. N Engl J Med. 2007 Sep 27;357(13):1316-25.
http://www.ncbi.nlm.nih.gov/pubmed/17898101?tool=bestpractice.com
[50]Fletcher BR, Damery S, Aiyegbusi OL, et al. Symptom burden and health-related quality of life in chronic kidney disease: a global systematic review and meta-analysis. PLoS Med. 2022 Apr;19(4):e1003954.
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003954
http://www.ncbi.nlm.nih.gov/pubmed/35385471?tool=bestpractice.com
Uremic illness is due largely to the accumulation of organic waste products that are normally cleared by the kidneys, and symptoms may be present to some degree in the early stages of kidney failure.[49]Meyer TW, Hostetter TH. Uremia. N Engl J Med. 2007 Sep 27;357(13):1316-25.
http://www.ncbi.nlm.nih.gov/pubmed/17898101?tool=bestpractice.com
As kidney failure progresses to the more advanced stages of uremia, patients will often describe anorexia, nausea, vomiting, restless legs, pruritus, fatigue, and feeling generally ill.[51]National Kidney Foundation. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis. 2015 Nov;66(5):884-930.
https://www.ajkd.org/article/S0272-6386(15)01019-7/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/26498416?tool=bestpractice.com
Changes in the frequency of urination (e.g., polyuria, oliguria, or nocturia) and appearance of urine are sometimes reported. Patients may describe their urine as foamy if significant proteinuria is present, or cola- or tea-colored in the setting of hematuria.[2]Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017 Mar 25;389(10075):1238-52.
http://www.ncbi.nlm.nih.gov/pubmed/27887750?tool=bestpractice.com
If patients begin to have a lack of urine production, resulting fluid overload may be present with dyspnea and orthopnea due to pulmonary edema. Cognition may be affected in all stages of CKD.[2]Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017 Mar 25;389(10075):1238-52.
http://www.ncbi.nlm.nih.gov/pubmed/27887750?tool=bestpractice.com
In the most advanced stages of uremia, patients may present with seizures or coma.[52]Arnold R, Issar T, Krishnan AV, et al. Neurological complications in chronic kidney disease. JRSM Cardiovasc Dis. 2016 Jan-Dec;5:2048004016677687.
https://journals.sagepub.com/doi/10.1177/2048004016677687
http://www.ncbi.nlm.nih.gov/pubmed/27867500?tool=bestpractice.com
Examination
Signs of CKD include hypertension, peripheral edema (due to sodium retention and exacerbated by hypoalbuminemia), and pallor due to anemia.[2]Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017 Mar 25;389(10075):1238-52.
http://www.ncbi.nlm.nih.gov/pubmed/27887750?tool=bestpractice.com
In patients with fluid overload/congestion, leg edema is usually bilateral and pitting; additional signs of fluid overload include pulmonary crepitations, dullness to percussion and decreased air entry in lung bases, wheezing, elevated jugular venous pressure, and ascites.
Assess for end-organ damage
Physical exam includes assessment of end-organ damage associated with causative disease states such as diabetes or hypertension. A fundoscopic eye exam is critical for the diagnosis of diabetic or hypertensive retinopathy as evidence of microvascular damage that has likely occurred in the kidney, resulting in CKD.
In men, a rectal exam for prostatic enlargement or for the diagnosis of prostate nodules can be helpful in determining a diagnosis of obstructive uropathy. In glomerular nephrotic and nephritic syndromes, the signs and symptoms of CKD may present more acutely with accelerated hypertension, periorbital and peripheral edema, rashes, or arthritis on musculoskeletal exam for patients with autoimmune disorders.[53]Khanna R. Clinical presentation & management of glomerular diseases: hematuria, nephritic & nephrotic syndrome. Mo Med. 2011 Jan-Feb;108(1):33-6.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188440
http://www.ncbi.nlm.nih.gov/pubmed/21462608?tool=bestpractice.com
Initial investigations
Most people are unaware that they have CKD and are informed only after abnormalities are discovered by blood and/or urine tests.[2]Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017 Mar 25;389(10075):1238-52.
http://www.ncbi.nlm.nih.gov/pubmed/27887750?tool=bestpractice.com
The first diagnostic tests to order are serum creatinine (as part of renal chemistry), estimated GFR (eGFR), and urinalysis to assess for hematuria and proteinuria.[1]Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024 Apr;105(4s):S117-314.
https://www.kidney-international.org/article/S0085-2538(23)00766-4/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/38490803?tool=bestpractice.com
[2]Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017 Mar 25;389(10075):1238-52.
http://www.ncbi.nlm.nih.gov/pubmed/27887750?tool=bestpractice.com
Interpretation of eGFR creatinine results should be individualized, including consideration of muscle mass. In circumstances where creatinine-based eGFR is less accurate or uncertain (e.g., extremes of muscle mass, above-knee amputation, BMI >40 kg/m²), cystatin C should be measured, if available, and GFR estimated using a combination of creatinine and cystatin C, or cystatin alone.[1]Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024 Apr;105(4s):S117-314.
https://www.kidney-international.org/article/S0085-2538(23)00766-4/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/38490803?tool=bestpractice.com
Laboratories should estimate GFR using an equation without a race variable.[54]National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management. Nov 2021 [internet publication].
https://www.nice.org.uk/guidance/ng203
[55]Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022 Feb;79(2):268-88.e1.
https://www.ajkd.org/article/S0272-6386(21)00828-3/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/34563581?tool=bestpractice.com
[56]Kramer HJ, Jaar BG, Choi MJ, et al. An endorsement of the removal of race from GFR estimation equations: a position statement from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Kidney Dis. 2022 Dec;80(6):691-6.
https://www.ajkd.org/article/S0272-6386(22)00859-9/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/36058427?tool=bestpractice.com
National Kidney Foundation: eGFR calculator
Opens in new window
[
Glomerular Filtration Rate Estimation (eGFR) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Equation with Creatinine, without Race (2021)
Opens in new window
]
Urinary albumin assessment is preferred to total urine protein, with calculation of the albumin to creatinine ratio (ACR) or the albumin excretion rate (AER).[1]Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024 Apr;105(4s):S117-314.
https://www.kidney-international.org/article/S0085-2538(23)00766-4/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/38490803?tool=bestpractice.com
[54]National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management. Nov 2021 [internet publication].
https://www.nice.org.uk/guidance/ng203
Albuminuria is both a diagnostic and a prognostic variable in the evaluation of patients with CKD.[2]Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017 Mar 25;389(10075):1238-52.
http://www.ncbi.nlm.nih.gov/pubmed/27887750?tool=bestpractice.com
[57]Levey AS, Gansevoort RT, Coresh J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in Collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020 Jan;75(1):84-104.
https://www.ajkd.org/article/S0272-6386(19)30883-2/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/31473020?tool=bestpractice.com
Nephrotic level proteinuria is conventionally defined as >3.5 g proteinuria per 24 hours.[58]Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4s):S1-276.
https://kdigo.org/wp-content/uploads/2024/05/KDIGO-2021-Glomerular-Diseases-Guideline_English_2024-Chapter-Updates.pdf
http://www.ncbi.nlm.nih.gov/pubmed/34556256?tool=bestpractice.com
Renal ultrasound may be used to evaluate kidney size, mass lesions, urinary tract obstruction, and, with a duplex examination, renal arterial flow.[59]Wong-You-Cheong JJ, Nikolaidis P, Katri G, et al; Expert Panel on Urologic Imaging. ACR appropriateness criteria® renal failure. J Am Coll Radiol. 2021 May;18(5s):S174-88.
https://www.jacr.org/article/S1546-1440(21)00154-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/33958111?tool=bestpractice.com
[60]Kalantar-Zadeh K, Jafar TH, Nitsch D, et al. Chronic kidney disease. Lancet. 2021 Aug 28;398(10302):786-802.
http://www.ncbi.nlm.nih.gov/pubmed/34175022?tool=bestpractice.com
Ultrasound is indicated in patients with a history of kidney stones or obstruction, renal artery stenosis, frequent urinary tract infections, or a family history of autosomal dominant polycystic kidney disease.[59]Wong-You-Cheong JJ, Nikolaidis P, Katri G, et al; Expert Panel on Urologic Imaging. ACR appropriateness criteria® renal failure. J Am Coll Radiol. 2021 May;18(5s):S174-88.
https://www.jacr.org/article/S1546-1440(21)00154-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/33958111?tool=bestpractice.com
Chronicity (duration of at least 3 months) may be established by review of history, past or repeat measurements, imaging findings (e.g., reduced kidney size and cortical thickness), or pathologic findings (e.g., fibrosis and atrophy).[1]Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024 Apr;105(4s):S117-314.
https://www.kidney-international.org/article/S0085-2538(23)00766-4/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/38490803?tool=bestpractice.com
Additional investigations
Comorbidities of CKD may not be identified unless intentionally assessed; therefore, comprehensive examination is important.
If not already known, consider screening for diabetes. See Type 2 diabetes mellitus in adults.
Anemia and secondary hyperparathyroidism are commonly seen in patients with later stages of CKD (GFR category G3-G5 [eGFR <15-59 mL/minute/1.73 m²]). Complete blood count (including hemoglobin concentration, red cell indices, white blood cell count and differential, and platelet count) and other tests for anemia (iron studies, vitamin B12) are recommended.[61]KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012 Aug;2(4):279-335.
https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf
Assessment for hyperparathyroidism includes measurement of calcium, phosphorus, and intact parathyroid hormone (PTH) levels.[62]Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7(1):1-59.
https://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf
Frequency of monitoring for anemia and secondary hyperparathyroidism depends on stage, with more frequent testing as CKD stage increases.
Biopsy and further imaging studies
Kidney biopsies are performed in a minority of patients with CKD to help evaluate cause and guide treatment.[1]Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024 Apr;105(4s):S117-314.
https://www.kidney-international.org/article/S0085-2538(23)00766-4/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/38490803?tool=bestpractice.com
A kidney biopsy to determine a pathologic diagnosis is indicated if a glomerular nephrotic or nephritic syndrome is suspected, or in people with diabetes with atypical presentations such as rapidly progressive kidney failure. Nephrotic syndrome may be suggested by proteinuria, and both nephritic and nephrotic syndromes may be suggested by severe presenting symptoms (accelerated hypertension, periorbital and peripheral edema) or with symptoms of underlying autoimmune diseases (rashes or arthritis). Certain infections, such as hepatitis B and C, syphilis, and streptococcal pharyngitis, are associated with glomerular disorders.[63]Chen D, Yu R, Yin S, et al. Hepatitis B virus infection as a risk factor for chronic kidney disease: a systematic review and meta-analysis. BMC Infect Dis. 2024 Jun 22;24(1):620.
https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-09546-z
http://www.ncbi.nlm.nih.gov/pubmed/38909191?tool=bestpractice.com
A kidney biopsy is critical in these cases to determine the correct diagnosis.[58]Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4s):S1-276.
https://kdigo.org/wp-content/uploads/2024/05/KDIGO-2021-Glomerular-Diseases-Guideline_English_2024-Chapter-Updates.pdf
http://www.ncbi.nlm.nih.gov/pubmed/34556256?tool=bestpractice.com
Imaging of the genitourinary tract may be helpful in the evaluation of a patient with CKD. A plain abdominal x-ray is a nonspecific test that may aid in the detection of calcium-containing kidney stones. Other radiologic tests are not used routinely.[59]Wong-You-Cheong JJ, Nikolaidis P, Katri G, et al; Expert Panel on Urologic Imaging. ACR appropriateness criteria® renal failure. J Am Coll Radiol. 2021 May;18(5s):S174-88.
https://www.jacr.org/article/S1546-1440(21)00154-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/33958111?tool=bestpractice.com
[60]Kalantar-Zadeh K, Jafar TH, Nitsch D, et al. Chronic kidney disease. Lancet. 2021 Aug 28;398(10302):786-802.
http://www.ncbi.nlm.nih.gov/pubmed/34175022?tool=bestpractice.com
Genetic testing is not carried out routinely, but may be useful in some cases to establish cause and inform management.[1]Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024 Apr;105(4s):S117-314.
https://www.kidney-international.org/article/S0085-2538(23)00766-4/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/38490803?tool=bestpractice.com
[64]Knoers N, Antignac C, Bergmann C, et al. Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice. Nephrol Dial Transplant. 2022 Jan 25;37(2):239-54.
https://academic.oup.com/ndt/article/37/2/239/6321895
http://www.ncbi.nlm.nih.gov/pubmed/34264297?tool=bestpractice.com
[65]Dahl NK, Bloom MS, Chebib FT, et al. The clinical utility of genetic testing in the diagnosis and management of adults with chronic kidney disease. J Am Soc Nephrol. 2023 Dec 1;34(12):2039-50.
https://journals.lww.com/jasn/fulltext/2023/12000/the_clinical_utility_of_genetic_testing_in_the.16.aspx
http://www.ncbi.nlm.nih.gov/pubmed/37794564?tool=bestpractice.com
Actionable genes in kidney diseases have been suggested by expert consensus.[1]Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024 Apr;105(4s):S117-314.
https://www.kidney-international.org/article/S0085-2538(23)00766-4/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/38490803?tool=bestpractice.com
[20]KDIGO Conference Participants. Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2022 Jun;101(6):1126-41.
https://www.kidney-international.org/article/S0085-2538(22)00278-2/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/35460632?tool=bestpractice.com